Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.26
IGC's Cash-to-Debt is ranked lower than
82% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.09 vs. IGC: 0.26 )
Ranked among companies with meaningful Cash-to-Debt only.
IGC' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.36 Max: N/A
Current: 0.26
Equity-to-Asset 0.68
IGC's Equity-to-Asset is ranked higher than
58% of the 734 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.64 vs. IGC: 0.68 )
Ranked among companies with meaningful Equity-to-Asset only.
IGC' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.35  Med: 0.68 Max: 0.77
Current: 0.68
0.35
0.77
Piotroski F-Score: 3
Altman Z-Score: -4.64
Beneish M-Score: -2.97
WACC vs ROIC
15.63%
-20.84%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating Margin % -146.08
IGC's Operating Margin % is ranked lower than
88% of the 744 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 8.42 vs. IGC: -146.08 )
Ranked among companies with meaningful Operating Margin % only.
IGC' s Operating Margin % Range Over the Past 10 Years
Min: -389.94  Med: -45.64 Max: 6.53
Current: -146.08
-389.94
6.53
Net Margin % -120.99
IGC's Net Margin % is ranked lower than
87% of the 745 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.16 vs. IGC: -120.99 )
Ranked among companies with meaningful Net Margin % only.
IGC' s Net Margin % Range Over the Past 10 Years
Min: -496.83  Med: -60.08 Max: -1.48
Current: -120.99
-496.83
-1.48
ROE % -20.30
IGC's ROE % is ranked lower than
80% of the 768 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.86 vs. IGC: -20.30 )
Ranked among companies with meaningful ROE % only.
IGC' s ROE % Range Over the Past 10 Years
Min: -128.75  Med: -20.04 Max: 2.94
Current: -20.3
-128.75
2.94
ROA % -14.58
IGC's ROA % is ranked lower than
79% of the 799 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.49 vs. IGC: -14.58 )
Ranked among companies with meaningful ROA % only.
IGC' s ROA % Range Over the Past 10 Years
Min: -75.62  Med: -12.66 Max: 2.22
Current: -14.58
-75.62
2.22
ROC (Joel Greenblatt) % -32.78
IGC's ROC (Joel Greenblatt) % is ranked lower than
78% of the 785 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.40 vs. IGC: -32.78 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
IGC' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -224.09  Med: -30.25 Max: 621.16
Current: -32.78
-224.09
621.16
3-Year Revenue Growth Rate -30.40
IGC's 3-Year Revenue Growth Rate is ranked lower than
93% of the 607 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.70 vs. IGC: -30.40 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
IGC' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: -41.8 Max: 275.6
Current: -30.4
0
275.6
3-Year EBITDA Growth Rate -19.60
IGC's 3-Year EBITDA Growth Rate is ranked lower than
86% of the 583 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9.40 vs. IGC: -19.60 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
IGC' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -70.6  Med: -57.75 Max: -19.6
Current: -19.6
-70.6
-19.6
3-Year EPS without NRI Growth Rate -19.00
IGC's 3-Year EPS without NRI Growth Rate is ranked lower than
81% of the 551 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. IGC: -19.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
IGC' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -69.8  Med: -29.1 Max: 74.6
Current: -19
-69.8
74.6
GuruFocus has detected 4 Warning Signs with India Globalization Capital Inc $IGC.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» IGC's 10-Y Financials

Financials (Next Earnings Date: 2017-08-17 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Insider Trades

Latest Guru Trades with IGC

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:OTCPK:AQSZF, OTCPK:LBLTF, OTCPK:RLMD, OTCPK:TLFMF, NAS:DCTH, OTCPK:CYIG, OTCPK:BKIT, OTCPK:EMMBF, OTCPK:AOLS, OTCPK:PUFXF, OTCPK:RSPI, OTCPK:PVCT, OTCPK:PARNF, NAS:APRI, OTCPK:ACUR, OTCPK:CBICF, NAS:MYOS, OTCPK:NRXCF, OTCPK:ICCLF, OTCPK:ADMD » details
Traded in other countries:IGS1.Germany,
Headquarter Location:USA
India Globalization Capital Inc is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions.

India Globalization Capital, Inc. is a Maryland corporation, organized on April 29, 2005. It is a materials and construction company offering services including: civil construction of roads and highways, the construction and maintenance of high temperature cement and steel plants, operations and supply of rock aggregate and the export of iron ore to China. The Company's present and past clients include various Indian government organizations and steel mills in China. Including its subsidiaries, it has approximately 200 employees and contractors. It is focused on winning construction contracts, building out rock aggregate quarries and setting up relations and export hubs for the export of iron ore to China. India has strict environmental, occupational, health and safety regulations.

Top Ranked Articles about India Globalization Capital Inc

NYSE MKT Extends India Globalization Capital Compliance Plan Period
IGC Files International Patents for IGC-501 Compound Indicated for Neuropathic Pain
IGC Sells Malaysian Hotel Investment Interest
India Globalization Capital Receives Letter from NYSE MKT LLC
IGC Files Patent for Cannabis-based Combination Therapy for Treatment of Eating Disorders

BETHESDA, Md., March 21, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (-MKT:IGC) today announces its provisional patent filing (IGC-506) for the treatment of multiple types of eating disorders by a method and combination of cannabis extracts and other compounds. IGC-506 is being developed for both human and veterinary use, should this filing progress to the issuance of a patent. “The development of cannabis-based combination therapies represents a large, unique opportunity, and we believe we are the first mover in this emerging specialty-pharmaceutical sector.  Over the past three years, we have built a strong IP portfolio and now propose to obtain funding to commence pre-clinical and clinical trials as appropriate. Securing FDA approval for combination therapies is generally much faster and less expensive than the process for new drug applications. As a result, we believe that we can bring our cannabis-based pharmaceutical products to market in both an expeditious and cost-effective manner,” states Ram Mukunda, Chief Executive Officer of IGC. As previously reported (http://nnw.fm/e6A76), IGC has started a review of international medical facilities to commence preclinical and clinical trials in support of the Company’s patent portfolio, which includes IGC-501 for neuropathic pain; IGC-502 for the treatment of seizures; and IGC-504 for eating disorders, including cachexia. It should be noted that filing a provisional patent does not guarantee the issuance of a patent in the future. Patent Portfolio & Market Application IGC-501 - indicated for neuropathic pain. The pain market represents a significant component of the U.S. health care system, costing between $560 billion-$635 billion per year, according to the most recent data from the Journal of Pain (2012). IGC-502 - indicated for seizures. Approximately 50 million people worldwide are affected by epilepsy (Sanders, 2003), a condition attributed to multiple factors. IGC-504 and IGC-506 - indicated for eating disorders, including cachexia, a condition that accompanies severe illness such as cancer and results in the weakness and wasting away of the body.  Approximately 1.3 million people in the United States are experiencing cachexia associated with cancer, multiple sclerosis, Parkinson’s disease, HIV/AIDS, and other progressive illnesses. Notably, cancer-induced anorexia/cachexia is responsible for about 20% of all cancer deaths. About IGC India Globalization Capital is engaged in the development of cannabis-based therapies to treat pain, PTSD, seizures, cachexia, chronic and terminal neurological and oncological diagnoses, and other life altering conditions.  In support of this mission, IGC has assembled a portfolio of patent filings for its phytocannabinoid-based treatments. The company is based in Bethesda, Maryland. For more information visit www.igcinc.us Follow us on Twitter @IGCIR and Facebook.com/IGCIR/
IGC Contact Info:
Claudia Grimaldi
General Manager
301.983.0998 Office

Read more...

Ratios

vs
industry
vs
history
PB Ratio 1.82
IGC's PB Ratio is ranked higher than
69% of the 770 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.03 vs. IGC: 1.82 )
Ranked among companies with meaningful PB Ratio only.
IGC' s PB Ratio Range Over the Past 10 Years
Min: 0.19  Med: 0.63 Max: 2.15
Current: 1.82
0.19
2.15
PS Ratio 4.14
IGC's PS Ratio is ranked lower than
62% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.90 vs. IGC: 4.14 )
Ranked among companies with meaningful PS Ratio only.
IGC' s PS Ratio Range Over the Past 10 Years
Min: 0.11  Med: 1.17 Max: 7.46
Current: 4.14
0.11
7.46
EV-to-EBIT -6.62
IGC's EV-to-EBIT is ranked lower than
99.99% of the 776 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.99 vs. IGC: -6.62 )
Ranked among companies with meaningful EV-to-EBIT only.
IGC' s EV-to-EBIT Range Over the Past 10 Years
Min: -433.8  Med: -2.7 Max: 88
Current: -6.62
-433.8
88
EV-to-EBITDA -9.43
IGC's EV-to-EBITDA is ranked lower than
99.99% of the 797 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.26 vs. IGC: -9.43 )
Ranked among companies with meaningful EV-to-EBITDA only.
IGC' s EV-to-EBITDA Range Over the Past 10 Years
Min: -47.7  Med: -2.9 Max: 53
Current: -9.43
-47.7
53
Current Ratio 2.41
IGC's Current Ratio is ranked lower than
52% of the 700 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.55 vs. IGC: 2.41 )
Ranked among companies with meaningful Current Ratio only.
IGC' s Current Ratio Range Over the Past 10 Years
Min: 0.97  Med: 1.88 Max: 22.08
Current: 2.41
0.97
22.08
Quick Ratio 2.41
IGC's Quick Ratio is ranked higher than
60% of the 699 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.85 vs. IGC: 2.41 )
Ranked among companies with meaningful Quick Ratio only.
IGC' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 1.64 Max: 22.08
Current: 2.41
0.95
22.08
Days Inventory 63.65
IGC's Days Inventory is ranked higher than
79% of the 689 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 117.29 vs. IGC: 63.65 )
Ranked among companies with meaningful Days Inventory only.
IGC' s Days Inventory Range Over the Past 10 Years
Min: 13.8  Med: 26.6 Max: 158.65
Current: 63.65
13.8
158.65
Days Sales Outstanding 117.02
IGC's Days Sales Outstanding is ranked lower than
75% of the 636 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 75.05 vs. IGC: 117.02 )
Ranked among companies with meaningful Days Sales Outstanding only.
IGC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 47.19  Med: 96.13 Max: 2321.79
Current: 117.02
47.19
2321.79
Days Payable 91.31
IGC's Days Payable is ranked higher than
65% of the 586 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 70.53 vs. IGC: 91.31 )
Ranked among companies with meaningful Days Payable only.
IGC' s Days Payable Range Over the Past 10 Years
Min: 6.2  Med: 25.66 Max: 362.54
Current: 91.31
6.2
362.54

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -49.40
IGC's 3-Year Average Share Buyback Ratio is ranked lower than
94% of the 442 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.30 vs. IGC: -49.40 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
IGC' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -84.6  Med: -42.15 Max: 10.3
Current: -49.4
-84.6
10.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 1.84
IGC's Price-to-Tangible-Book is ranked higher than
74% of the 705 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.61 vs. IGC: 1.84 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
IGC' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 0.25  Med: 1.05 Max: 5.13
Current: 1.84
0.25
5.13
Price-to-Median-PS-Value 3.54
IGC's Price-to-Median-PS-Value is ranked lower than
92% of the 645 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.13 vs. IGC: 3.54 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
IGC' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.11  Med: 1.08 Max: 5.07
Current: 3.54
0.11
5.07
Earnings Yield (Greenblatt) % -15.14
IGC's Earnings Yield (Greenblatt) % is ranked lower than
87% of the 1046 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.36 vs. IGC: -15.14 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
IGC' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -15.43  Med: 6.75 Max: 15.1
Current: -15.14
-15.43
15.1

More Statistics

Revenue (TTM) (Mil) $2.07
EPS (TTM) $ -0.12
Beta2.57
Short Percentage of Float0.09%
52-Week Range $0.19 - 0.80
Shares Outstanding (Mil)24.27
» More Articles for IGC

Headlines

Articles On GuruFocus.com
NYSE MKT Extends India Globalization Capital Compliance Plan Period Apr 21 2017 
IGC Files International Patents for IGC-501 Compound Indicated for Neuropathic Pain Apr 10 2017 
IGC Sells Malaysian Hotel Investment Interest Apr 05 2017 
India Globalization Capital Receives Letter from NYSE MKT LLC Apr 04 2017 
IGC Files Patent for Cannabis-based Combination Therapy for Treatment of Eating Disorders Mar 21 2017 

More From Other Websites
India Globalization Capital, Inc. (IGC) Engages NetworkNewsWire for Corporate Communications... Apr 25 2017
NYSE MKT Extends India Globalization Capital Compliance Plan Period Apr 21 2017
IGC Files International Patents for IGC-501 Compound Indicated for Neuropathic Pain Apr 10 2017
IGC Sells Malaysian Hotel Investment Interest Apr 05 2017
India Globalization Capital Receives Letter from NYSE MKT LLC Apr 04 2017
NetworkNewsWire Announces Publication that Highlights Pain-Reducing Combination Therapies by... Mar 31 2017
NetworkNewsWire Releases Exclusive Audio Interview with India Globalization Capital, Inc. (IGC) Mar 23 2017
India Globalization Capital, Inc. :IGC-US: Earnings Analysis: Q3, 2017 By the Numbers : March 21,... Mar 21 2017
IGC Files Patent for Cannabis-based Combination Therapy for Treatment of Eating Disorders Mar 21 2017
NetworkNewsWire Announces Publication that Reviews Cannabis-Pharma Companies Making Waves in the... Mar 17 2017
IGC Announces Third Quarter Financial Results Feb 21 2017
India Globalization Capital Announces the Extension of Warrants’ Expiry Date and Inducement Grant... Feb 17 2017
IGC Launches Phytocannabinoid Development Committee to Secure Preclinical Initiatives for IGC-501,... Feb 13 2017
India Globalization Capital, Inc. :IGC-US: Earnings Analysis: Q2, 2017 By the Numbers : November 22,... Nov 22 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)